BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Atreya R, Peyrin-Biroulet L, Klymenko A, Augustyn M, Bakulin I, Slankamenac D, Miheller P, Gasbarrini A, Hébuterne X, Arnesson K, Knittel T, Kowalski J, Neurath MF, Sandborn WJ, Reinisch W; CONDUCT study group. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. Lancet Gastroenterol Hepatol 2020;5:1063-75. [PMID: 33031757 DOI: 10.1016/S2468-1253(20)30301-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Grossberg LB, Papamichael K, Cheifetz AS. Review: emerging drug therapies in inflammatory bowel disease. Aliment Pharmacol Ther 2022. [PMID: 35166398 DOI: 10.1111/apt.16785] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Su S, Wang X, Xi X, Zhu L, Chen Q, Zhang H, Qin Y, Yang B, Che N, Cao H, Zhong W, Wang B. Phellodendrine promotes autophagy by regulating the AMPK/mTOR pathway and treats ulcerative colitis. J Cell Mol Med 2021;25:5707-20. [PMID: 34002930 DOI: 10.1111/jcmm.16587] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Sawayama H, Miyamoto Y, Yoshida N, Baba H. Essential updates 2020/2021: Colorectal diseases (benign)—Current topics in the surgical and medical treatment of benign colorectal diseases. Annals of Gastroent Surgery. [DOI: 10.1002/ags3.12548] [Reference Citation Analysis]
4 Atreya R, Neurath MF. [Inflammatory bowel diseases - therapy update 2022]. Dtsch Med Wochenschr 2022;147:295-300. [PMID: 35291033 DOI: 10.1055/a-1585-4026] [Reference Citation Analysis]
5 Al-Bawardy B, Shivashankar R, Proctor DD. Novel and Emerging Therapies for Inflammatory Bowel Disease. Front Pharmacol 2021;12:651415. [PMID: 33935763 DOI: 10.3389/fphar.2021.651415] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
6 Rath T, Atreya R, Neurath MF. Is histological healing a feasible endpoint in ulcerative colitis? Expert Rev Gastroenterol Hepatol 2021;15:665-74. [PMID: 33481635 DOI: 10.1080/17474124.2021.1880892] [Reference Citation Analysis]
7 Yamamoto-Furusho JK, Parra-Holguín NN. Emerging therapeutic options in inflammatory bowel disease. World J Gastroenterol 2021; 27(48): 8242-8261 [DOI: 10.3748/wjg.v27.i48.8242] [Reference Citation Analysis]
8 Caron B, Sandborn WJ, Panaccione R, Schreiber S, Hart A, Solitano V, Danese S, Peyrin-Biroulet L. Efficacy of pharmacological agents for ulcerative proctitis: a systematic literature review. J Crohns Colitis 2021:jjab218. [PMID: 34850857 DOI: 10.1093/ecco-jcc/jjab218] [Reference Citation Analysis]